Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Alzamend Neuro, Inc.

NASDAQ: ALZN · Life Sciences · 2 alerts · CIK 1677077

Share price
$1.18Close, Nov 16
Market cap
$5.69M
Shares outstanding
4.83MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Alzamend Neuro, Inc. filings on SEC EDGAR ↗

4:31 PM ET 8-K/A
Capital Raise

Alzamend Neuro Capital Raise of $10M

Alzamend Neuro entered into an Amended and Restated Securities Purchase Agreement with Ault Lending, LLC to sell $10 million in Series D convertible preferred stock. This amends a previous agreement for $25 million, with $7.5 million already raised in an initial tranche and an additional $2.5 million committed for a second tranche closing.

Value
$10M
Counterparty
Ault Lending, LLC
6:30 AM ET 8-K
Clinical Trial Data

Alzamend Neuro Clinical Trial Data

Alzamend Neuro presented Phase 1/2A clinical trial data for AL001, a novel organic lithium salt, at the ISMRT Conference. The study utilized 7T MRI imaging to evaluate brain pharmacokinetics, demonstrating that AL001 is designed for improved brain delivery with lower systemic exposure compared to standard inorganic lithium salts.

Counterparty
Massachusetts General Hospital

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.